The global anti-diabetes therapy market is undergoing a massive transformation, with the advent of GLP-1 ‘wonder drugs’ fundamentally reshaping the treatment landscape.  Against this backdrop, it is particularly interesting to examine developments in the domestic Indian market – often referred to as the ‘diabetes capital of the world’. India has the second-largest diabetic population globally,  with ~11% of adults living with diabetes (~90mn people). This is projected to rise